Tags : guselkumab

Viewpoints

PharmaShots Interview: Dr. Philip Mease Shares Insights on the Clinical

In an interview with PharmaShots, Dr. Philip Mease, MD, Seattle Rheumatology Associates shares insights on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in The Lancet Rheumatology Shots: The P-III trials consist of two studies i.e., DISCOVER-1 & 2 evaluates Tremfya in 1100 patients with PsA who have axial symptoms The results demonstrated efficacy […]Read More

Biotech

Janssen Expands Clinical Development for Tremfya(R) (guselkumab) in Familial Adenomatous

Shots: Janssen has initiated P-Ib proof-of-concept clinical trial assessing Guselkumab vs PBO in 72 patients with familial adenomatous polyposis (FAP). With the initiation of P-Ib study for FAP, MorphoSys will receive milestones from Janssen Earlier, Janssen collaborated with MorphoSys to develop Guselkumab utilizing MorphoSys’s HuCAL antibody technology (Human Combinatorial Antibody Library), a platform for invitro […]Read More